高级检索
当前位置: 首页 > 详情页

Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]The Second Clinical College of Guangzhou University of Chinese Medicine,Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120,People’s Republic of China [2]Department of Critical Care Medicine,Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120,People’s Republic of China [3]Department of Cardiology, Yichang Hospital ofChinese Medicine, Clinical Medical College of Chinese Medicine, China ThreeGorges University, Yichang 443000, People’s Republic of China
出处:
ISSN:

关键词: Hyperuricemia Coronary heart disease Mortality Meta-analysis

摘要:
Background: Hyperuricemia may be associated with an increased risk of coronary heart disease (CHD) mortality; however, the results from prospective studies are conflicting. The objective of this study was to assess the association between hyperuricemia and risk of CHD mortality by performing a meta-analysis. Methods: Pubmed and Embase were searched for relevant prospective cohort studies published until July 2015. Studies were included only if they reported data on CHD mortality related to hyperuricemia in a general population. The pooled adjusted relative risk (RR) was calculated using a random-effects model. Results: A total of 14 studies involving 341 389 adults were identified. Hyperuricemia was associated with an increased risk of CHD mortality (RR: 1.14; 95 % CI: 1.06-1.23) and all-cause mortality (RR: 1.20; 95 % CI: 1.13-1.28). For each increase of 1 mg/dl of serum uric acid (SUA), the overall risks of CHD and all-cause mortality increased by 20 and 9 %, respectively. According to the gender subgroup analyses, hyperuricemia increased the risk of CHD mortality in women (RR: 1.47; 95 % CI: 1.21-1.73) compared to men (RR: 1.10; 95 % CI: 1.00-1.19). The risk of all-cause mortality was greater in women. Conclusions: Hyperuricemia may modestly increase the risk of CHD and all-cause mortality. Future research is needed to determine whether urate-lowering therapy has beneficial effects for reducing CHD mortality.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统
最新[2025]版:
大类 | 3 区 医学
小类 | 4 区 心脏和心血管系统
JCR分区:
出版当年[2014]版:
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
最新[2023]版:
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

影响因子: 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者机构: [1]The Second Clinical College of Guangzhou University of Chinese Medicine,Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120,People’s Republic of China [2]Department of Critical Care Medicine,Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120,People’s Republic of China
共同第一作者:
通讯作者:
通讯机构: [1]The Second Clinical College of Guangzhou University of Chinese Medicine,Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120,People’s Republic of China [2]Department of Critical Care Medicine,Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120,People’s Republic of China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号